Opportunities for Improvement: The Lot of the Inhibitor Patient Is Not a Happy One

CONCLUSION: In examining recruits into the present trial, it is clear that inhibitor patients have generally worse functional scores than either of two reference groups. Effective long-term prophylaxis is expected to produce measurable improvement in QOL scores in this hard-to-treat population.DisclosuresBooth: Catalyst Biosciences: Consultancy. Mahlangu: Sanofi: Research Funding, Speakers Bureau; Roche: Consultancy, Research Funding, Speakers Bureau; LFB: Consultancy; NovoNordisk: Consultancy, Research Funding, Speakers Bureau; CSL Behring: Consultancy, Research Funding, Speakers Bureau; Chugai: Consultancy; Catalyst Biosciences: Consultancy, Research Funding; Biomarin: Research Funding, Speakers Bureau; Biogen: Research Funding, Speakers Bureau; Bayer: Research Funding; Amgen: Consultancy; Alnylam: Consultancy, Research Funding, Speakers Bureau; Shire: Consultancy, Research Funding, Speakers Bureau; Sobi: Research Funding, Speakers Bureau; Spark: Consultancy, Research Funding. Levy: Catalyst Biosciences: Employment, Equity Ownership.

Source: Blood - November 21, 2018 Category: Hematology Authors: Booth, F. V. M., Mahlangu, J., Levy, H. Tags: 322. Disorders of Coagulation or Fibrinolysis Source Type: research